PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 16, 2006Lara D. Veeken58 citationsOpen Access

Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol

View Full Paper
GMG MilioECEgle CorradoCGC Genova

Key Points

Key points are not available for this paper at this time.

Abstract

In patients with systemic sclerosis, cyclic intravenous iloprost infusion is efficacious in the treatment of Raynaud's phenomenon. The protocol that we used, compared with others, not only has favourable clinical effects but also leads to a marked improvement in the quality of life.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Milio et al. (2006) studied this question.

synapsesocial.com/papers/69dbcc239e6f14d6f168440ahttps://doi.org/10.1093/rheumatology/kel038
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Measuring disease activity and severity in scleroderma.1995 · 37 citations
  2. 2Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity1995 · 138 citations
  3. 3Vascular Disease in Scleroderma1990 · 62 citations
  4. 4Lymphocyte interactions with the vascular endothelium in systemic sclerosis1994 · 15 citations
  5. 5The endothelium in the pathogenesis of systemic sclerosis: is it primary or secondary?1999 · 8 citations